<DOC>
	<DOCNO>NCT01598025</DOCNO>
	<brief_summary>Approximately 30 % patient candidate bone marrow transplant HLA-matched , close match , donor available . For reason , doctor test way make transplant HLA-partially match donor safe effective transplant HLA-matched donor . This study do test safety treatment result specific kind transplant . In transplant , blood two donor use . Each donor share one half HLA type . Blood donor transplant time .</brief_summary>
	<brief_title>Biparental HLA Haplotype Disparate T-cell Depleted Transplants Patients Lacking HLACompatible Donor</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Malignant condition CD34+ select , Tcell deplete allogeneic hematopoietic stem cell transplantation indicate : AML 1st remission patient whose AML 'good risk ' cytogenetic feature ( i.e . 8 ; 21 , t15 ; 17 , inv 16 ) . Secondary AML 1st remission AML 1st relapse &gt; 2nd remission ALL/LL 1st remission clinical molecular feature indicate high risk relapse ; ALL &gt; 2nd remission CML fail respond tolerate Imatinib , dasatinib , nilotinib first chronic phase disease ; CML accelerate phase second chronic phase . NonHodgkins lymphoma chemoresponsive disease follow category : ) intermediate high grade lymphoma fail achieve first CR relapse follow 1st remission candidate autologous transplant . NHL remission consider curable chemotherapy alone eligible/appropriate autologous transplant . Myelodysplastic syndrome ( MDS ) : RA/RCMD high risk cytogenetic feature transfusion dependence , RAEB1 RAEB2 Acute myelogenous leukemia ( AML ) evolve MDS , eligible transplantation protocol IRB 08008 . Chronic myelomonocytic leukemia : CMML1 CMML2 . Other rare lethal disorder Hematopoiesis Lymphopoiesis Tcell deplete transplant indicate ( e.g . hemophagocytic lymphohistiocytosis ; refractory aplastic anemia conjugate cytopenia ; nonSCID lethal genetic immunodeficiency Wiskott Aldrich Syndrome , CD40 ligand deficiency , ALPS ) . Patients may either gender racial ethnic background . Patients must Karnofsky ( adult ) Lansky ( pediatric ) Performance Status &gt; 70 % . Patients must adequate organ function measure : Cardiac : asymptomatic symptomatic LVEF rest must &gt; 50 % must improve exercise . Hepatic : &lt; 3x ULN ALT &lt; 2.0x ULN total serum bilirubin , unless congenital benign hyperbilirubinemia . Renal : serum creatinine &lt; 1.2 mg/dl serum creatinine outside normal range , CrCl &gt; 40 ml/min ( measure calculated/estimated ) Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Female patient pregnant breastfeed Uncontrolled viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II Presence leukemia CNS . Donor Each donor must meet criterion outline institutional policy Donor must adequate peripheral venous catheter access leukapheresis must agree placement central catheter . Donor Evidence active infection ( include urinary tract infection , upper respiratory tract infection ) , viral hepatitis exposure ( screen ) , unless HBS Ab+ HBV DNA negative , serologic evidence exposure infection HIVI/II HTLVI/II If donor meet institutional guideline , exclusion consider .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ANTITHYMOCYTE GLOBULIN : ATG</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>THI0TEPA</keyword>
	<keyword>CliniMACS-CD34 Reagent System</keyword>
	<keyword>12-053</keyword>
</DOC>